Overall Survival and Efficacy Subgroup Analysis of Tunlametinib in Patients with Advanced NRAS-mutant Melanoma: A Multicenter, Open-Label, Single-Arm, Phase 2 Study.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined